Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$8.63
$0.18(4.59%)
At close: 4:00 PM EST
$8.63
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$3.79 - $11.45
Previous CloseN/A
Volume1.97M
Average Volume (3M)2.29M
Market Cap
$832.88M
Enterprise Value$429.99
Total Cash (Recent Filing)$381.32M
Total Debt (Recent Filing)$20.67M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 17, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding98,449,610
10 Day Avg. Volume1,180,039
30 Day Avg. Volume2,294,545
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.75Price Target Upside94.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Modest DebtModest absolute debt and low debt-to-equity reduce fixed financing burdens for a clinical-stage biotech. Structurally, low leverage preserves flexibility to allocate cash to R&D, absorb trial delays, and seek non-debt funding without large interest drains over the next several quarters.
Expanded Financing Optionality (Authorized Shares)Doubling authorized shares is a durable corporate action that increases capacity for future equity financings or strategic transactions. Combined with board and auditor continuity, it materially improves the company’s ability to raise capital for multi-stage clinical programs without operational disruption.
Focused Genetic-Medicine Platform (DMD)A dedicated platform targeting genetic medicines and a clear emphasis on DMD align the company with structural industry growth in gene therapy. Specialized expertise and a focused pipeline can sustain competitive differentiation and attract partnerships or targeted funding over the medium term.
Bears Say
No Meaningful Revenue; Widening LossesThe absence of commercial revenue and materially widening net losses create a persistent funding gap. Over 2–6 months this fundamental constraint forces management to prioritize financing strategies over organic reinvestment, heightening execution risk if clinical progress slips or milestones are delayed.
High Cash Burn / Negative Free Cash FlowConsistently large negative operating and free cash flow indicate the company cannot self-fund development. Structurally high burn increases the likelihood of frequent dilutive financings and can interrupt R&D momentum if capital markets tighten or financing terms deteriorate over the coming quarters.
Dependence On External Financing / Dilution RiskVolatile, rising equity levels signal reliance on capital raises instead of internal cash generation. Paired with the newly expanded share authorization, this structural reliance increases dilution risk for existing shareholders and can pressure long-term returns as further equity issuances become necessary to sustain development.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $832.88M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.429 by -$0.091.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.46.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 98,449,610 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.429. Following the earnings report the stock price went down -4.404%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.75 (94.09% Upside)
$16.75 (94.09% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.97%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$16.75
▲(94.09% Upside)
Technical Analysis
Ownership Overview
13.16% Insiders
10.87% Mutual Funds
0.37% Other Institutional Investors
62.38% Public Companies and
Individual Investors